Ultragenyx Pharmaceutical Inc
For the period ended Dec 31, 2024. Filed Feb 19, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 19, 2025
RARE$16.14-1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| (In thousands, except share amounts) · Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · Treasury · Deferred Compensation · TotalStockholders' | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income (Loss) | Deficit | Stock | Obligation | Equity | |
| Balance as of December 31, 2021 | 69,344,998 | $69 | $2,997,497 | $(1,404) | $(2,073,601) | $— | $— | $922,561 |
| Stock-based compensation | — | — | 131,710 | — | — | — | — | 131,710 |
| Issuance of common stock under equity plan awards, net of tax | 852,299 | 1 | 10,812 | — | — | — | — | 10,813 |
| Other comprehensive loss | — | — | — | (5,169) | — | — | — | (5,169) |
| Net loss | — | — | — | — | (707,421) | — | — | (707,421) |
| Balance as of December 31, 2022 | 70,197,297 | $70 | $3,140,019 | $(6,573) | $(2,781,022) | $— | $— | $352,494 |
| Issuance of common stock and pre-funded warrants in connection with underwritten public offering, net of issuance costs | 9,833,334 | 10 | 326,446 | — | — | — | — | 326,456 |
| Issuance of common stock in connection with at-the-market offering, net of issuance costs | 1,175,584 | 1 | 53,298 | — | — | — | — | 53,299 |
| Stock-based compensation | — | — | 134,169 | — | — | — | — | 134,169 |
| Issuance of common stock under equity plan awards, net of tax | 1,109,375 | 1 | 8,414 | — | — | — | — | 8,415 |
| Deferred compensation | — | — | — | — | — | (432) | 432 | — |
| Other comprehensive income | — | — | — | 7,220 | — | — | — | 7,220 |
| Net loss | — | — | — | — | (606,639) | — | — | (606,639) |
| Balance as of December 31, 2023 | 82,315,590 | $82 | $3,662,346 | $647 | $(3,387,661) | $(432) | $432 | $275,414 |
| Issuance of common stock and pre-funded warrants in connection with underwritten public offering, net of issuance costs | 8,782,051 | 9 | 380,974 | — | — | — | — | 380,983 |
| Stock-based compensation | — | — | 158,115 | — | — | — | — | 158,115 |
| Issuance of common stock under equity plan awards, net of tax | 1,386,689 | 1 | 11,257 | — | — | — | — | 11,258 |
| Deferred compensation | — | — | — | — | — | (3,161) | 3,161 | — |
| Other comprehensive loss | — | — | — | (1,290) | — | — | — | (1,290) |
| Net loss | — | — | — | — | (569,183) | — | — | (569,183) |
| Balance as of December 31, 2024 | 92,484,330 | $92 | $4,212,692 | $(643) | $(3,956,844) | $(3,593) | $3,593 | $255,297 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.